Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
patent cliff
Pharma
Patent cliffs face BMS, Merck, Pfizer but all can pull off M&A
BMS, Pfizer and Merck will face patent cliff exposure later in this decade but all have the financial flexibility to compensate with M&A, Moody's says
Kevin Dunleavy
Jun 21, 2022 4:14pm
The top 10 drugs losing US exclusivity in 2022
Mar 8, 2022 3:00am
Bristol Myers notes 3 key launches to counter Revlimid losses
Jan 10, 2022 3:03pm
BMS, Amgen and Pfizer face steepest patent cliffs
Dec 29, 2021 9:56am
AbbVie's court win extends the life of blockbuster Imbruvica
Aug 31, 2021 11:03am
The top 15 blockbuster patent expirations coming this decade
Jul 12, 2021 3:00am
